The chat tool is available to ask questions or comments at any time during this event.
RAISE YOUR HAND

If you wish to speak telephonically, please “raise your hand.” We will call your name, when your phone line is unmuted.
ENGAGE AT OUR NEW WEBSITE!

Network with peers, learn how essential hospitals are changing lives
Now live at essentialhospitals.org
AGENDA

• Partnership for Patients and 2014
• AHRQ PSI-12 and Postoperative VTE after TKA (Banafsheh Sadeghi, MD, PhD)
• VTE prevention system (Anneliese Schleyer, MD, MHA/Ellen F. Robinson, PT)
• Q & A
• Upcoming events
2014 PARTNERSHIP FOR PATIENTS

**Partnership for Patients (PfP)**
- CMS-funded
- Reduce nine hospital-acquired conditions by 40 percent
- Reduce readmissions by 20 percent

**Hospital Engagement Networks (HENs)**
- 27 contracted organizations
- 3,700 U.S. hospitals

**Essential Hospitals Engagement Network (EHEN)**
- 22 hospitals nationwide
- Only essential hospital-focused HEN
- Special focus on health equity
MEMBERS-ONLY VTE RESOURCES

• VTE tab includes
   » Resources
   » Links
   » Discussion thread
   » Recordings of past webinars

• [http://essentialhospitals.org/groups/ehen/venous-thromboembolism/](http://essentialhospitals.org/groups/ehen/venous-thromboembolism/)
Post-Operative Pulmonary Embolism or DVT, Medicare FFS (PSI 12)
EHEN VTE: PE/DVT RATE (ALL DISCHARGES)
[UHC-MODIFIED AHRQ PSI-12]

Baseline 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87 1.87

Rate 2.71 1.97 2.57 2.21 1.78 2.50 2.31 1.62 1.70 2.08 2.07 1.46 1.43 1.45 1.63 1.48 2.14 1.92 2.32 1.97 1.79 2.59 2.68 1.81 1.96 2.07 1.45 1.26 2.00 2.06 1.76 1.31 2.03 1.39 1.93 2.01

SPEAKER INFORMATION

Banafsheh Sadeghi, M.D., Ph.D.
Assistant Adjunct Professor, School of Medicine
UC Davis Department of Internal Medicine
Sacramento, CA

Anneliese Schleyer, MD, MHA
Associate Medical Director of Hospital Quality and Patient Safety
Harborview Medical Center
Seattle, WA

Ellen F. Robinson, PT
Manager, Quality Improvement
Harborview Medical Center
Seattle, WA
Overview AHRQ Quality Indicators: PSIs

- The AHRQ Patient Safety Indicators (PSIs)
- In hospital complications and adverse events following surgeries, procedures, and childbirth.
- Comprehensive literature review, analysis of ICD-9-CM codes
AHRQ Quality Indicators: PSIs

• Improve the safety of inpatient care
• Public reporting and pay-for-performance
• Identify potentially avoidable events
• Incidence of adverse events and in hospital complications
• using administrative data
  – hospital avoidable adverse events
  – regional level avoidable adverse event

www.quality_indicators.ahrq.gov/psi_download.htm
Patient Safety Indicators #12 (PSI #12) Numerator

- Discharges, among cases meeting the inclusion and exclusion rules for the denominator, with a secondary ICD-9-CM diagnosis code for deep vein thrombosis or a secondary ICD-9-CM diagnosis code for pulmonary embolism.

- **ICD-9-CM Deep vein thrombosis diagnosis codes1:**
  - 45111, 45119, 4512, 45181, 4519, 45340, 4538, 4539

- **ICD-9-CM Pulmonary embolism diagnosis codes1:**
  - 4151, 41513, 41511, 41519
Postoperative Venous Thromboembolism (PSI #12)

Denominator

• Surgical discharges, for patients ages 18 years and older, with any-listed ICD-9-CM procedure codes for an operating room procedure. Surgical discharges are defined by specific DRG or MS-DRG codes.

Exclude cases:

• with a principal ICD-9-CM diagnosis code (or secondary diagnosis present on admission) for deep vein thrombosis (see above)
• with a principal ICD-9-CM diagnosis code (or secondary diagnosis present on admission) for pulmonary embolism (see above)
• where the only operating room procedure is interruption of vena cava
• where a procedure for interruption of vena cava occurs before or on the same day as the first operating room procedure†
• MDC 14 (pregnancy, childbirth, and puerperium)
• with missing gender (SEX=missing), age (AGE=missing), quarter (DQTR=missing), year (YEAR=missing), or principal diagnosis (DX1=missing)
More Information

www.ahrq.gov
Mechanical and Suboptimal Pharmacologic Prophylaxis and Delayed Mobilization but Not Morbid Obesity Are Associated With Venous Thromboembolism After Total Knee Arthroplasty: A Case-Control Study

Sadeghi B, Romano PS, Maynard G, Strater AL, Hensley L, Cerese J, White RH.

The annual incidence of TKA ranged from 1.6% to 11.9% in males and from 2.0% to 10.9% in females.

Weinstein AM1, Rome BN, Reichmann WM, Collins JE, Burbine SA, Thornhill TS, Wright J, Katz JN, Losina E.
Possible TKA Complications

- **Infection.** Major or deep infections may require more surgery and removal of the prosthesis.

- **VTE.** Blood clots in the leg veins are the most common complication of knee replacement surgery. PE can be life-threatening.

- **Implant problems.** Implant surfaces may wear down and the components may loosen. Additionally, although an average of 115° of motion is generally anticipated after surgery, scarring of the knee can occasionally occur, and motion may be more limited.

- **Continued pain.** A small number of patients continue to have pain after a knee replacement. This complication is rare.

- **Neurovascular injury.** While rare, injury to the nerves or blood vessels around the knee can occur during surgery.
VTE Prophylaxis after TKA

• Most guidelines from North America recommend the use of postoperative low-molecular-weight heparin (LMWH), fondaparinux, or warfarin for at least 10 days after TKA.
VTE Prophylaxis after TKA

Thromboprophylaxis reduces the risk of developing asymptomatic VTE by more than 60%.

Pharmacologic prophylaxis using LMWH, fondaparinux, or warfarin alone is recommended by the ACCP and other organizations, with use of mechanical pneumatic compression, low-dose unfractionated heparin, or aspirin as alternative options.
Study Hypothesis and Goals:

1. Use of standard pharmacological thromboprophylaxis drug is associated with lower risk of acute VTE compared with mechanical prophylaxis only.

2. Among patients given LMWH/fondaparinux, excessive obesity (BMI>35) is associated with a higher risk of developing VTE.

3. Delayed ambulation after TKA is associated with higher risk for VTE.
Methods: Partnership

- Univ. of California Davis (UCD)
  - 631-bed hospital serves
  - key referral center for 33 counties and 6 million residents.
  - Northern California’s only level I trauma center
  - UC Davis Medical Center ranks among the top 50 hospitals in America according to annual U.S. News & World Report survey

- University HealthSystem Consortium (UHC)
  - UHC is an alliance of 120 academic medical centers and 299 of their affiliated hospitals.
Methods: Study Design

• Retrospective case-control study.
• Fifteen volunteer hospitals nationwide abstracted medical records up to 40.

Cases:
• Having one or more secondary diagnosis codes for VTE as defined by AHRQ PSI-12 coupled with a POA flag of “no”
• Were readmitted with principal diagnosis of VTE within 90 days of date of surgery

Controls:
• Patients who did not develop acute VTE during the index hospitalization or within 90 days of surgery.
Methods: Inclusion & Exclusion Criteria

• Inclusion:
  – Admission between Oct. 1, 2008 and March 31, 2010;
  – ICD-9-CM procedure code of 81.54 or 81.55;
  – Age of 40 years or more;

• Exclusion:
  – Pregnancy related principal diagnosis;
  – Inferior vena cava interruption on or before the date of the first operating room procedure.
Data Collection: Chart Abstraction Tool

A chart abstraction tool was constructed and personnel at each site were taught how to obtain the desired information.
Data Collection: Chart Abstraction Tool

Data elements:
- Age
- Gender
- Height
- Weight
- Type of TKA
- Use of pharmacologic and mechanical prophylaxis
- Ambulation status

Types of prophylaxis categories:
1. LMWH/fondaparinux with or without mechanical prophylaxis;
2. Warfarin alone, with or without mechanical prophylaxis;
3. LMWH/fondaparinux and warfarin with or without mechanical prophylaxis;
4. Mechanical prophylaxis (Pneumatic compression devices, graduated compression stockings, or foot pump) alone (without any pharmacological prophylaxis but with or without aspirin);
5. Aspirin only, without any other pharmacologic or mechanical prophylaxis.

FDA-approval status:
- FDA-approved
- Pharmacologic prophylaxis
- Other prophylaxis
Outcome of Study

• Principal outcome:
  – Validated symptomatic objectively confirmed VTE
  • Patients with VTE on the day of surgery or the day after surgery were not included in the principal analysis.

• Statistical analysis:
  – Bivariate analysis: student t-test, chi-square, unadjusted Odds Ratio (OR)
  – Multivariate analysis: logistic regression and two-way interactions adjusted for correlated data, using SAS-PC 9.2
Results:

Total of 593 TKA record were abstracted.
All patients underwent TKA on the day of admission or the day after:

– 114 cases (44 PE, 68 DVT, 2 both)
– 463 controls
– 16 cases (12 PE and 4 DVT) excluded.
Result: Bivariate Analysis

• Age in cases significantly higher than controls: 65.5±10.4 vs. 63.5±10.4 (P<0.05)

• Cases underwent more bilateral: 23% vs. 7% (P< 0.001)

• Cases had marginally higher BMI than controls: 34.6± 8.0 vs. 33.3 ±7.1 (P = 0.07)
  • Among PE cases, there were more morbidly obese cases compared with controls: 30% vs. 16% (P = 0.01)
Result: Bivariate Analysis

- Fewer VTE cases began ambulation on or before the second post-op day compared with controls: 47% vs. 73% (P<0.001).

- All patients received at least 1 type of pharmacological or mechanical prophylaxis within 24 hrs. after TKA.

- Controls had marginally higher odds of receiving FDA-approved pharmacologic prophylaxis than cases 61% vs. 48% (P = 0.07).
## Results: Multivariable Analysis

<table>
<thead>
<tr>
<th>Predictive Factor</th>
<th>Odds Ratio (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td>1.02 (0.99 – 1.05)</td>
<td>0.20</td>
</tr>
<tr>
<td><strong>Gender (ref: male)</strong></td>
<td>1.7 (0.9 – 2.9)</td>
<td>0.90</td>
</tr>
<tr>
<td><strong>Ambulation (ref: no ambulation)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Taking steps day 1 or 2</td>
<td>0.3 (0.1 – 0.9)</td>
<td>0.005</td>
</tr>
<tr>
<td>• Taking steps after day 2</td>
<td>0.7 (0.2 – 2.1)</td>
<td>0.56</td>
</tr>
<tr>
<td><strong>Type of TKA (ref: unilateral TKA)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Bilateral TKR</td>
<td>4.2 (1.9 – 9.1)</td>
<td>0.004</td>
</tr>
<tr>
<td><strong>Recommended pharmacologic prophylaxis (ref: only mechanical)</strong></td>
<td>0.5 (0.3 – 0.8)</td>
<td>0.01</td>
</tr>
<tr>
<td><strong>BMI ≥ 35 (ref: BMI &lt; 35)</strong></td>
<td>0.9 (0.5 – 1.6)</td>
<td>0.66</td>
</tr>
</tbody>
</table>
Results: Prophylaxis

• FDA-approved pharmacologic prophylaxis:
  – LMWH, fondaparinux, or warfarin
    Odds Ratio = 0.5; 95% CI: 0.3 – 0.8, P-value= 0.01

• Risk of VTE across the BMI levels
Results: Ambulation

• Early mobilization in the first 2 days after:
  – Odds Ratio = 0.3, 95% CI: 0.1 – 0.9, P-value = 0.005

• Mobilization at or after day 3
Results: Bilateral vs. Unilateral

• Bilateral simultaneous TKA strongly associated with VTE:
  – Odds Ratio = 4.2, 95% CI: 1.9 – 9.1, P-value <0.001
  – The effect still existed after adjusting for obesity or time of mobilization.
Study limitations

• No record of readmission to other hospitals
• Effect of hospital volume and specialization
• Data collection by employees and no double collection
• All teaching hospitals
• Inherent case-control limitations
• Actionable opportunities to improve care to prevent VTE persist despite 100% compliance with existing TJC process measures
• FDA approved pharmacologic prophylaxis
• Early mobilization
• Bilateral vs. unilateral
• AHRQ PSI#12
• Further research studies needed
# Evidence-Based Clinical Practice Guidelines

<table>
<thead>
<tr>
<th>Guideline</th>
<th>Accepted VTE Prophylaxis</th>
<th>Defined Risk</th>
</tr>
</thead>
</table>
| American College of Chest Physicians: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed. | One of the following for 10-14 days  
- LMWH started ≥ 12 h before or after surgery  
- Low-dose unfractionated heparin  
- Factor Xa inhibitor (fondaparinux, apixaban, rivaroxaban)  
- Warfarin  
- Dabigatran  
- Recommends against the use of aspirin alone for any group  
- In patients with elevated bleeding risk:  
  - Intermittent pneumatic compression device (18 hours daily) | Total knee surgeries are considered high risk for VTE, regardless of age, activity level, or comorbidities |
| American Academy of Orthopedic Surgeons | Pharmacologic prophylaxis as above  
Mechanical prophylaxis for patients with elevated bleeding risk:  
- Pneumatic compression devices  
- Foot and leg pumps | Total knee surgeries are considered standard risk for PE. Bleeding risk defined as:  
- History of a bleeding disorder  
- History of recent gastrointestinal bleed  
- History of recent hemorrhagic stroke |
| Surgical Care Improvement Project | LMWH  
- Factor Xa inhibitor (fondaparinux)  
- Warfarin  
- Intermittent pneumatic compression devices  
- Venous foot pump | Orthopedic surgeries with surgical time > 60 min and LOS > 3 days |
Q & A

Banafsheh Sadeghi, M.D., Ph.D.
Assistant Adjunct Professor, School of Medicine
UC Davis Department of Internal Medicine
Sacramento, CA
Today’s Objectives

• Describe Multidisciplinary VTE Team
• Discuss innovative approaches that have reduced post-operative DVT/PE
• Outline systematic event review methods
• Provide overview of the tools developed for engaging front line staff
Harborview Medical Center

Key Centers of Excellence

- Level I adult and pediatric trauma and burn care
- Neurosciences Institute
- Orthopaedic reconstruction and rehabilitation
- Comprehensive Eye Institute and vision science center
- Vascular
- Behavioral health
- AIDS/STD

2012 Statistics

- Licensed beds: 413
- Employees: 4,664
- Physicians: 1,243
- Admissions: 19,094
- Emergency Department visits: 62,432
- Clinic visits: 247,246
- Surgery cases: 14,872

Charity Care

Provided $210 million in charity care in fiscal year 2012.
VTE Team Members

• Physician Co-Chair – Surgeon and Hospitalist
• Pharmacy – clinical, safety, administration
• Nursing – trauma, clinical education
• Quality Improvement – analyst, programmer
• Input from Orthopedic, Neurology, Neurosurgery physicians, EMAR IT analysts, UWMC pharmacy team, discharge planning
VTE Case Reviews

*Hospital Acquired VTE*

- Clinical information for quality review imbedded complex electronic medical record (EMR - Cerner)
- Time consuming, not systematic
- Created an electronic tool to allow for efficient monthly team review

- For all HAC VTE

- Team reviews following elements for guideline adherence
  - Risk Assessment performed
  - Chemical Prophylaxis timing, drug selection, dosing
  - Mechanical Prophylaxis utilized if chemical not appropriate
  - Charted Contraindications
Team review utilizing pertinent data points
- Source system for PE/VTE identification
- Radiology (NLP), Vascular (coded event)
- Reason for admission
- Labs, BMI
- VTE Risk Assessment
- Chemical administered
- Mechanical administered
- Surgery impact, held doses

* J Hosp Med 2014 Jan; 9(1) 48-53
## From Retrospective to “Real Time”

<table>
<thead>
<tr>
<th>Room</th>
<th>Admit Date</th>
<th>Age</th>
<th>LOS</th>
<th>Reason</th>
<th>INR</th>
<th>SCD</th>
<th>Drug Dose</th>
<th>Drug Ordered</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>2013-12-09</td>
<td>15:35</td>
<td></td>
<td>LEFT INTERTROCHANTERIC FEMUR, FRACTURE; LEFT PARASYMPHYSEAL PELVIC FRACTURE</td>
<td>1.1</td>
<td>OFF</td>
<td>Not Given: Pt still on PNC enoxaparin 2013-12-11 21:00</td>
<td>Not Given: Pt still on PNC enoxaparin 2013-12-11 21:00</td>
</tr>
<tr>
<td>9</td>
<td>2013-12-03</td>
<td>11:40</td>
<td></td>
<td>LUMBAR 2 BURST FRACTURE</td>
<td>1.1</td>
<td>OFF</td>
<td>Not Done: hold per MD order, capping PNC’s in am enoxaparin 2013-12-11 21:00</td>
<td>Not Done: hold per MD order, capping PNC’s in am enoxaparin 2013-12-11 21:00</td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>Ulcer of other part of foot</td>
<td></td>
<td>OFF</td>
<td></td>
<td>Not Ordered</td>
</tr>
<tr>
<td>4</td>
<td>2013-12-08</td>
<td>16:30</td>
<td></td>
<td>GUN SHOT WOUND TO LEFT HAND</td>
<td>1.0</td>
<td>None Applied</td>
<td></td>
<td>Not Ordered</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td>Acquired spondylolisthesis</td>
<td></td>
<td>ON</td>
<td></td>
<td>Not Ordered</td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>Spondylolisthesis of lumbar region</td>
<td></td>
<td>ON</td>
<td></td>
<td>Not Ordered</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td>Hallux valgus (acquired)</td>
<td></td>
<td>ON</td>
<td>40 mg enoxaparin 2013-12-11 09:00</td>
<td>Not Ordered</td>
</tr>
<tr>
<td>11</td>
<td>2013-12-12</td>
<td>07:26</td>
<td></td>
<td>LEFT HUMERUS FRACTURE</td>
<td>1.1</td>
<td>OFF</td>
<td>5,000 units heparin 2013-12-05 17:00</td>
<td>Not Ordered</td>
</tr>
<tr>
<td>1</td>
<td>2013-12-12</td>
<td>06:22</td>
<td></td>
<td>SUBARACHNOID HEMORRHAGE</td>
<td>0.9</td>
<td>None Applied</td>
<td></td>
<td>Not Ordered</td>
</tr>
<tr>
<td>1</td>
<td>2013-12-11</td>
<td>22:00</td>
<td></td>
<td>Spinal stenosis, lumbar region, without neurogenic claudication</td>
<td>1.2</td>
<td>ON</td>
<td></td>
<td>Not Ordered</td>
</tr>
<tr>
<td>1</td>
<td>2013-12-12</td>
<td>04:45</td>
<td></td>
<td>GASTROINTESTINAL BLEED</td>
<td>1.7</td>
<td>None Applied</td>
<td>warfarin 2013-12-11 19:39</td>
<td>Not Ordered</td>
</tr>
<tr>
<td>2</td>
<td>2013-12-12</td>
<td>04:12</td>
<td></td>
<td>POLYTRAUMA</td>
<td>1.0</td>
<td>None Applied</td>
<td></td>
<td>Not Ordered</td>
</tr>
<tr>
<td>6</td>
<td>2013-12-12</td>
<td>06:05</td>
<td></td>
<td>Gunshot Wound to the Left Chest and Neck</td>
<td>1.0</td>
<td>None Applied</td>
<td>Not Given: Patient Refused heparin 2013-12-12 01:00</td>
<td>Not Given: Patient Refused heparin 2013-12-12 01:00</td>
</tr>
</tbody>
</table>

Intervention can be related to resident, nursing or patient education.
Guideline Directed Prophylaxis

Cases that do not adhere to guidelines per VTE team review sent for secondary review to each medical service and results reported through Medical QI Committee

![VTE Guideline Adherence Chart](image)

This document was created specifically for, and collected and maintained by a quality improvement program or committee and is not subject to discovery or introduction into evidence in any civil action. This document contains confidential QI information pursuant to RCW 70.41.200 (3) and 4.24.250; any joint preparation or sharing of this information with another coordinated QI program is pursuant to the protection of RCW 70.41 and 43.70.510.
SCIP/VTE Prophylaxis Core Measures

HMC Core Measures SCIP
Appropriate Venous Thromboembolism Prophylaxis Received within 24 hrs

- Q1 2014: No Failures
- VBP Threshold: 94.9, VBP Benchmark: 99.9%

Venous Thromboembolism - Prophylaxis Acute Care and ICU

- March 2014: SCDs ordered but not placed - 2W, 7E

UW Medicine
HARBORVIEW MEDICAL CENTER
Expanding to “All Patients”

• Take findings from Case Reviews and implement system change for all hospitalized patients

• Areas for ongoing improvement
  – VTE Risk Assessment
  – Chemical prophylaxis dosing
  – Held chemical doses
  – SCD utilization
Ongoing Improvement – VTE Risk Assessment

CPOE VTE Prophylaxis order set April 2013
Allowed Risk Assessment to be captured

Ongoing Monthly Monitoring (March 2014)
93% of inpatients had risk assessed

Educated Epilepsy to assess risk
Medical and Surgical Teams educating “high risk” versus “at risk”
Ongoing Improvement – Enoxaparin Dosing
Prophylactic enoxaparin doses (6 months admissions)
30mg and 40mg; q12h and q24h

- Analysis to compare Risk Assessment to drug dosing by a review of on patient clinical factors/disease process
- 47% were accurately “Risk Assessed”
  - Reasons related to Trauma patients “at risk” \((high\ risk)\)
  - Patients with history of/active cancer “at risk” \((high\ risk)\)
- 85% received the correct dosing
  - Reasons related to BMI > 40 - given 30 mg dosing
  - CCRL > or < 30 given 30 vs. 40 mg dosing
  - Trauma patients given Q24 vs. Q12 dosing
Ongoing Improvement – Held Doses
3 months of chemical prophylaxis reviewed

• Enoxaparin – 88% given – 12% Held
  • Majority related to OR

• Heparin – 85% given – 15% held
  • Majority related to Ambulatory or Not appropriate
Held for OR by Service

Variation for Holding doses: May be appropriate for certain cases
Working to standardize practice across services

Enoxaparin

Heparin
Held Doses: “Ambulating” and “Refused” By Nursing Unit

“Ambulating”

“Patient Refused”

This document was created specifically for, and collected and maintained by a quality improvement program or committee and is not subject to discovery or introduction into evidence in any civil action. This document contains confidential QI information pursuant to RCW 70.41.200 (3) and 4.24.250; any joint preparation or sharing of this information with another coordinated QI program is pursuant to the protection of RCW 70.41 and 43.70.510.
Ongoing Improvement - SCDs

<table>
<thead>
<tr>
<th>Service</th>
<th>Admit Dt</th>
<th>Admit Reason</th>
<th>SCD Order Reason (may be blank)</th>
<th>Order By</th>
<th>Last Chart</th>
<th>Chart By</th>
<th>Chart Dt</th>
</tr>
</thead>
<tbody>
<tr>
<td>H SURGERY II</td>
<td>12/5/2013 1:23:00 PM</td>
<td>pleural effusion; other pneumothorax; ot...</td>
<td>Contraindication to pharmacologic VTE prophylaxis. Continue until pharmacologic prophylaxis is started.</td>
<td>OFF Legs - Bilaterally</td>
<td>12/12/2013 12:30:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>H SURGERY I</td>
<td>12/7/2013 5:10:00 PM</td>
<td>pancreas injury nos-clo; inj liv no op w...</td>
<td>Contraindication to pharmacologic VTE prophylaxis. Continue until pharmacologic prophylaxis is started.</td>
<td>OFF Legs - Bilaterally</td>
<td>12/12/2013 12:15:00 AM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>H THORACIC SURGERY</td>
<td>11/28/2013 2:33:00 PM</td>
<td>atrial fibrillation; occlu,sten caroid ...</td>
<td>Contraindication to pharmacologic VTE prophylaxis. Continue until pharmacologic prophylaxis is started.</td>
<td>OFF Legs - Bilaterally</td>
<td>12/12/2013 12:10:00 AM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>H SURGERY II</td>
<td>12/7/2013 6:17:00 PM</td>
<td>swelling of limb; nb subarachnoid hemorr...</td>
<td>Contraindication to pharmacologic VTE prophylaxis. Continue until pharmacologic prophylaxis is started. Do not place on RLE!!!</td>
<td>OFF Legs - Bilaterally</td>
<td>12/11/2013 8:15:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>H SURGERY II</td>
<td>12/7/2013 6:23:00 PM</td>
<td>traumatic subdural hem; other and unspec...</td>
<td>Contraindication to pharmacologic VTE prophylaxis. Continue until pharmacologic prophylaxis is started.</td>
<td>OFF Legs - Bilaterally</td>
<td>12/11/2013 9:35:00 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>H ORTHOPEDICS</td>
<td>12/3/2013 11:04:00 AM</td>
<td>joint pain-upper arm; pain in limb; fx l...</td>
<td>Contraindication to pharmacologic VTE prophylaxis. Continue until pharmacologic prophylaxis is started.</td>
<td>OFF Legs - Bilaterally</td>
<td>12/11/2013 8:16:00 PM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Daily review – 30 to 35 patients per day had SCD orders with the devices charted as “off” sometime in the previous 24 hours

Allows for real time education interventions with nursing staff
Results: Rate of VTE – PSI 12

Focus on VTE prevention has resulted in a decrease in VTE events
VTE 6 - Incidence of Potentially Preventable VTE

### Harborview Medical Center Jul - Sep 2013 (Q3)
#### VTE-6 Incidence of Potentially Preventable Venous Thromboembolism %

**Definition:** The percentage of patients diagnosed with confirmed VTE during hospitalization (not POA) who did not receive VTE prophylaxis during hospital admission and the day before the VTE diagnostic testing order date.

**Denominator:** Patients who developed confirmed VTE during hospitalization. Excludes patients less than 18 years of age who have a LOS greater than 120 days; with comfort measures only; enrolled in clinical trials; with a principal diagnosis code of VTE; with VTE POA; with reasons for not administering mechanical and pharmacologic prophylaxis; without VTE confirmed by diagnostic testing.

**Numerator:** Patients who received no VTE prophylaxis prior to the VTE diagnostic test order date.

**Target:** The Joint Commission target upper limit

**National Mean:** The mean of all comparison group observed rates obtained from the Core Measure National Comparison Group File.

**See Also:** [http://www.jointcommission.org/performance_measurement.aspx](http://www.jointcommission.org/performance_measurement.aspx)

<table>
<thead>
<tr>
<th>Current Quarter</th>
<th>Nuterator (n)</th>
<th>Denom (n)</th>
<th>Observed</th>
<th>UHC Median-TJC Method</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases (denom.)</td>
<td>24</td>
<td>79</td>
<td>2</td>
<td>4</td>
<td>11</td>
</tr>
<tr>
<td>Oberved</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>9.8</td>
</tr>
<tr>
<td>Target</td>
<td>5.2</td>
<td>5.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>National Mean</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Recent Year**

<table>
<thead>
<tr>
<th>Nuterator (n)</th>
<th>Denom (n)</th>
<th>Observed</th>
<th>UHC Median-TJC Method</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cases (denom.)</td>
<td>88.0</td>
<td>66</td>
<td>10</td>
<td>15</td>
</tr>
<tr>
<td>Oberved</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>2.0</td>
</tr>
<tr>
<td>Target</td>
<td>5.2</td>
<td>5.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>National Mean</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Recent Year UHC Top 10 in this Metric**

<table>
<thead>
<tr>
<th>Facility Name</th>
<th>Score</th>
<th>Rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Ohio State University Wexner Medical Center</td>
<td>0.0</td>
<td>77</td>
</tr>
<tr>
<td>Mayo Clinic Hospital - Rochester</td>
<td>0.0</td>
<td>75</td>
</tr>
<tr>
<td>UC Irvine Medical Center</td>
<td>0.0</td>
<td>67</td>
</tr>
<tr>
<td>UCIrvine Memorial Health Care</td>
<td>0.0</td>
<td>58</td>
</tr>
<tr>
<td>Beaumont Hospital, Troy</td>
<td>0.0</td>
<td>31</td>
</tr>
<tr>
<td>Cedars-Sinai Medical Center</td>
<td>1.2</td>
<td>85</td>
</tr>
<tr>
<td>The Cleveland Clinic Foundation</td>
<td>1.8</td>
<td>168</td>
</tr>
<tr>
<td>Rush University Medical Center</td>
<td>1.0</td>
<td>56</td>
</tr>
</tbody>
</table>

*To qualify, facilities must meet the metric target and have an annual volume of at least 30 cases. Fewer than 10 facilities will be listed if less than 10 facilities meet these criteria.*
Conclusion

• Systematic Processes have resulted in a decrease in VTE events
• Success of the project can be attributed to physician leadership, communicated expectations, and front line staff engagement

• Questions and contact:
  • Ellen Robinson, PT (206) 744 9550  Inrobin@u.washington.edu
  • Anneliese Schleyer, MD, MHA, FHM  schleyer@u.washington.edu
Q & A

Anneliese Schleyer, MD, MHA
Associate Medical Director of Hospital Quality and Patient Safety
Harborview Medical Center
Seattle, WA

Ellen F. Robinson, PT
Manager, Quality Improvement
Harborview Medical Center
Seattle, WA
UPCOMING EVENTS

• Webinar: Antimicrobial Stewardship and *C. difficile* Infection
  June 5, 2-3 pm ET
**VITAL2014**, America's Essential Hospitals’ annual conference, is coming to San Antonio! Plan now to join us Wednesday, June 25, through Friday, June 27, at the Westin Riverwalk for the premier national event for hospital and health system professionals. Together, we will support our shared mission of ensuring high-quality health care for vulnerable patients.

THANK YOU FOR ATTENDING

• **Evaluation**: When you close out of WebEx following the webinar, an evaluation will open in your browser. Please take a moment to complete. We greatly appreciate your feedback!

• **Check out the NEW Essential Hospitals Engagement Network website**: [http://essentialhospitals.org/groups/ehen/](http://essentialhospitals.org/groups/ehen/)